# Micot

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/micot

- Industry: Biotechnology
- Headquarters: Xi'an, China
- Website: www.micot.cn
- Total disclosed funding: $71M
- Latest round: Series D (Oct 10, 2025)
- Investors on record: 10

## About

Based in Xi'an, China and established in 2007, Shaanxi Micot Pharmaceutical Technology Co., Ltd., dba Micot, is a biotechnology company specializing in the discovery, development and commercialization of bi-/multi-specific peptide drugs for the treatment of metabolic diseases as well as cardiovascular and cerebrovascular diseases. The company has research and operation center in the United States, and has set up branch offices in Suzhou, Shanghai, and Hong Kong. In 2024 one of the company's pipelines completed Phase III trials.

In January 2025, the company was converted into a joint stock company. In June 2026, Micot raised HKD approximately 1.06 billion in an IPO, selling nearly 58.05 million shares at CNY 18.2 apiece on the Hong Kong Exchanges and Clearing (HKEX) under the ticker "2335".

Micot focuses on the research and development of novel molecular drugs for bi-functional and multifunctional specific peptides, having developed multiple candidate drugs for metabolic and cardiovascular and cerebrovascular diseases. The company's core product, MT1013, is the dual-targeting receptor agonist polypeptide that simultaneously targets the CaSR (Calcium-Sensing Receptor) and the OGP (Osteogenic Growth Peptide) receptor, designed for the treatment of CKD-SHPT (Chronic Kidney Disease-induced Secondary Hyperparathyroidism), CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder) with Osteoporosis and CKD-SHPT not on Dialysis.

Micot generates revenue by developing peptide drugs, adopting dual-track commercialization approach: domestically through collaborations with third party Contract Sales Organizations (CSOs) and internationally via license-out partnerships.

Following the IPO on HKEX in June 2026, Micot plans to accelerate the clinical development of its core product and key product candidates, continue to focus on major disease areas such as metabolic disorders (particularly renal-related) and cardiovascular and cerebrovascular diseases to develop differentiated treatment solutions with differentiated advantages, deepen strategic collaborations with industry participants both domestically and overseas, and recruit and retain talents to promote systematic training and sustainable development.

## Funding rounds

- Series D, Oct 10, 2025 — Zheshang Venture Capital, Shaanxi Jinzi Fund Management, Shaanxi New Era Capital
- Series C, Feb 10, 2023, $15M — Changan Huitong Capital
- Series B, May 21, 2021, $56M — NLVC, SND Ventures Group, Tasly Holding Group, FC Capital - China, ShangJin Capital, NRL Capital

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Series B
- SND Ventures Group (https://capitalatlas.ai/funds/snd-ventures-group) — Series B
- Tasly Holding Group — Series B
- FC Capital - China (https://capitalatlas.ai/funds/fc-capital-china) — Series B
- ShangJin Capital — Series B
- NRL Capital (https://capitalatlas.ai/funds/nrl-capital) — Series B
- Changan Huitong Capital (https://capitalatlas.ai/funds/changan-huitong-capital) — Series C
- Zheshang Venture Capital (https://capitalatlas.ai/funds/zheshang-venture-capital) — Series D
- Shaanxi Jinzi Fund Management (https://capitalatlas.ai/funds/shaanxi-jinzi-fund-management) — Series D
- Shaanxi New Era Capital (https://capitalatlas.ai/funds/shaanxi-new-era-capital) — Series D